Prospective randomised sibling-oocyte study using recombinant human hyaluronidase Cumulase® versus Sigma hyaluronidase in intracytoplasmic sperm injection patients

ISRCTN ISRCTN89831716
DOI https://doi.org/10.1186/ISRCTN89831716
Secondary identifying numbers Protocol number: HZ2-05-07, NL953 (NTR979)
Submission date
27/06/2007
Registration date
27/06/2007
Last edited
25/10/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Josiane van der Elst
Scientific

Laboratory Director
Centre for Reproductive Medicine
Universitair Ziekenhuis Brussel
Laarbeeklaan 101
Brussels
B-1090
Belgium

Phone +32 24 77 66 90
Email Josiane.Vanderelst@uzbrussel.be

Study information

Study designRandomised, active controlled, parallel group trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific titleProspective randomised sibling-oocyte study using recombinant human hyaluronidase Cumulase® versus Sigma hyaluronidase in intracytoplasmic sperm injection patients
Study objectivesNon-inferiority trial in order to evaluate the effectiveness of the new compound (recombinant human hyaluronidase or Cumulase®), effectiveness being defined by intactness after Intracytoplasmic Sperm Injection (ICSI) and fertilisation rate.
Ethics approval(s)Approval received from the local medical ethics committee (Academisch Ziekenhuis - Vrije Universiteit Brussel) on the 2nd March 2006 (ref: Protocol HZ2-05-07, version 1.0 dd. 27/12/2005).
Health condition(s) or problem(s) studiedIntracytoplasmic Sperm Injection (ICSI), Hyaluronidase
InterventionOocyte collection and denudation:
At the moment of oocyte retrieval (day 0), sibling Cumulus Oocyte Complexes(COC's) were allocated to two separate oocyte collection dishes in an alternating way. A computer generated random list (balanced blocks of six) was used for allocation of the first dish to either Cumulase® or bovine hyaluronidase denudation.

Collection and denudation of the oocytes was done in Hepes buffered Human Tubal Fluid (HTF) medium (Cambrex Bioscience, Verviers, Belgium) supplemented with Synthetic Serum Supplement (SSS) (Irvine Scientific, Wicklow, Ireland). Cumulase® denudation (Halozyme Therapeutics Inc., San Diego, USA) involved incubation in 80 U/ml, including Pasteur pipetting of all sibling COC’s together (time of incubation to be determined during the study). When most of the cumulus was removed, oocytes were rinced twice in HTF medium prior to further mechanical decoronisation in the absence of the enzyme. The level of additional mechanical stripping was quantified by counting the number of times that individual oocytes had to be pipetted in and out of a small hand-made pipette (inner diameter 135 µm) using a Swemed pipette holder (Vitrolife, Kungsbacka, Sweden). Denudation in bovine hyaluronidase (Type VIII, Sigma Chemical Company, St Louis, USA) was done similarly except for using a 40 U/ml concentration of the enzyme, because of long-term laboratory experience with this concentration. Incubation time and level of mechanical stripping were evaluated similarly.

Incubation time of the cumulus oocyte complexes was 62 and 63 seconds for Cumulase® and bovine hyaluronidase respectively. Duration of follow up was until positive human Chorionic Gonadotropin (hCG) (i.e. 14 to 17 days post oocyte retrieval).

Baseline outcome measures:
Enzyme incubation time, mechanical denudation and number of mature oocytes available for ICSI are measured at the moment of oocyte denudation, which takes place immediately or ± 2 hours after oocyte retrieval (day 0). ICSI is performed on mature oocytes immediately after denudation.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Cumulase®, sigma hyaluronidase
Primary outcome measure1. Oocyte intactness after ICSI, measured ± 18 - 20 hours after ICSI (day 1 of culture)
2. Fertilisation rate, measured ± 18 - 20 hours after ICSI (day 1 of culture)
Secondary outcome measures1. Embryo development:
1.1. Day 3 embryo development is assessed on day 3 of embryo culture
1.2. Day 5 embryo development is assessed on day 5 of embryo culture
2. Positive human Chorionic Gonadotropin (hCG) after embryo transfer, measured in two blood samples given day 14 and day 17 after oocyte retrieval (day 0)
Overall study start date01/05/2006
Completion date28/02/2007

Eligibility

Participant type(s)Patient
Age groupAdult
SexFemale
Target number of participants135
Key inclusion criteriaWomen undergoing ICSI treatment with fresh ejaculate sperm cells, no older than 38 years of age and presenting between 8 and 16 Cumulus Oocyte Complexes (COC's) at ovum pick up.
Key exclusion criteria1. Surgically extracted sperm preparations
2. Embryo biopsy cycles
3. Women older than 38 years
4. Women with less than 8 or more than 16 COC's
Date of first enrolment01/05/2006
Date of final enrolment28/02/2007

Locations

Countries of recruitment

  • Belgium
  • Netherlands

Study participating centre

Laboratory Director
Brussels
B-1090
Belgium

Sponsor information

University Hospital Brussels (Universitair Ziekenhuis Brussel [UZ Brussel]) (Belgium)
Hospital/treatment centre

Centrum Medische Genetica en Centrum Reproductieve Geneeskunde
Brussels
B-1090
Belgium

Website http://www.uzbrussel.be
ROR logo "ROR" https://ror.org/038f7y939

Funders

Funder type

Industry

Halozyme Therapeutics Inc. (USA)

No information available

University Hospital Brussels (Universitair Ziekenhuis Brussel [UZ Brussel]) (Belgium)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Abstract results 01/06/2007 25/10/2021 No No

Editorial Notes

25/10/2021: Publication reference added.